StudyFinder

Search Results Within Category "Breathing, Lung & Sleep Health"

Here are the studies that match your search criteria. If you are interested in participating, please reach out to the contact listed for the study. If no contact is listed, contact us and we'll help you find the right person.

Search all categories
10 Study Matches

VX21-522-001: A Phase 1 Single Dose Escalation Study Evaluating the Safety and Tolerability of VX-522 in Subjects 18 Years of Age and Older With Cystic Fibrosis and a CFTR Genotype Not Responsive to CFTR Modulator Therapy

This is a clinical research study exploring the safety and tolerability of a single dose of VX-522 for people with cystic fibrosis (CF) who are not expected to benefit from CFTR modulators.

Joanne Billings
18 years and over
This study is NOT accepting healthy volunteers
SITE00001585
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• 18 to 65 years old
• Stable cystic fibrosis disease
• FEV1 at least 40%
• Specific CFTR gene mutations
Exclusion Criteria:

• Uncontrolled asthma in the last year
• Oxygen saturation without oxygen therapy is >94%
• Severe liver disease
Rare Diseases, Breathing, Lung & Sleep Health
Cystic Fibrosis, CF
I'm interested
Share via email
See this study on ClinicalTrials.gov

Efficacy and safety of GLP-1 agonist therapy in overweight and obese subjects with cystic fibrosis-related diabetes: a pilot study

In this study we will be looking at the safety and effectiveness of the medication GLP-1 (Semaglutide) in patients who are overweight and have been diagnosed with Cystic Fibrosis Related Diabetes (CFRD).

Amir Moheet
18 years and over
This study is NOT accepting healthy volunteers
STUDY00018575
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• diagnosis of cystic fibrosis
• diabetic using insulin
• BMI 26 kg/m2 or greater
• able to read & speak English
Exclusion Criteria:

• personal or family history of medullary thyroid cancer
• chronic GI problems requiring hospitalization in the past year
• history of suicide attempts or active ideas of suicide
Rare Diseases, Breathing, Lung & Sleep Health
Cystic Fibrosis, Clinics and Surgery Center (CSC)
I'm interested
Share via email
See this study on ClinicalTrials.gov

MT2022-27: TRANSPIRE: Lung Injury in a Longitudinal Cohort of Pediatric HSCT Patients

Primary Purpose: To identify risk factors and mechanisms of lung injury, test novel diagnostic strategies and treatments to reduce morbidity and mortality from lung injury after transplant.

Samuel Goldfarb
Up to 24 years old
This study is NOT accepting healthy volunteers
SITE00001589
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• up to 24 years old
• undergoing allogeneic or autologous HSCT
Breathing, Lung & Sleep Health
Diffuse Alveolar Hemorrhage, Hematopoietic Stem Cell Transplant (HSCT), Interstitial Pneumonitis
I'm interested
Share via email
See this study on ClinicalTrials.gov

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Intravenous Efzofitimod in Patients with Pulmonary Sarcoidosis

We are studying the use of Efzofitimod given IV at two different doses to treat people who have pulmonary sarcoidosis. Participants must be on stable treatment with an oral corticosteroid with or without immunosuppressant therapy. Some people will receive IV saline (placebo) and we will compare groups to see how well the drug works and what side effects occur. The trial will last for about one year.

Maneesh Bhargava
18 years and over
This study is NOT accepting healthy volunteers
SITE00001630
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• Diagnosis of pulmonary sarcoidosis with some respiratory symptoms
• Must be taking stable dose of at least 7.5 mg of prednisone daily for 3 months and willing to taper dose down
• Body weight between 88-352 lbs
• Please contact umnsarc@umn.edu if you have any questions
Exclusion Criteria:

• Active heavy smoker (defined as > 20 cigarettes/day or e-cigarette equivalent)
• Active substance abuse (drugs, alcohol, or cannabis) or history of substance abuse within the last 12 months
• Pregnancy or breast-feeding
Rare Diseases, Breathing, Lung & Sleep Health, Respiratory System
Sarcoidosis, Clinics and Surgery Center (CSC)
I'm interested
Share via email
See this study on ClinicalTrials.gov

A Phase 2, Double-Blind, Randomized, Active-Control, Parallel Group Study to Assess the Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Safety of INBRX-101 Compared to Plasma Derived Alpha1-Proteinase Inhibitor (A1PI) Augmentation Therapy in Adults with Alpha-1 Antitrypsin Deficiency (AATD) Emphysema (ELEVAATE)

This study is for people who have emphysema (a disorder where too much air collects deep in the lungs) that is caused by the lack of a protein called alpha-1 antitrypsin (AAT) in the body. A deficiency of AAT (AATD) can damage lung and liver if not treated. The goal of this study is to evaluate the safety and study the therapeutic effects of INBRX-101 in subjects with AATD emphysema when compared with current approved AATD therapy with A1PI, known as Zemaira®.

Ronald Reilkoff
18 years and over
This study is NOT accepting healthy volunteers
SITE00001985
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• age 18 to 80
• diagnosis of Alpha 1-Antitrypsin Deficiency (AATD)
• symptoms of emphysema related to AATD
• currently not smoking
Exclusion Criteria:

• diagnosis of type 1 diabetes or diagnosed with uncontrolled type 2 diabetes
• on waiting list for lung or liver transplant
• active cancers or has a history of cancer within past 5 years
• significant congestive heart failure
• additional exclusion criteria (study staff will review)
Breathing, Lung & Sleep Health
Clinics and Surgery Center (CSC), Alpha 1-Antitrypsin Deficiency, Emphysema
I'm interested
Share via email
See this study on ClinicalTrials.gov

R01HL153613: Comprehensive Proteomic Classifier for the Molecular Characterization of Pulmonary Sarcoidosis

This study proposes to collect lung fluid to identify potential biomarkers associated with pulmonary sarcoidosis.

Maneesh Bhargava
18 years and over
This study is NOT accepting healthy volunteers
SITE00001283
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• age 18-80
• contact umnsarc@umn.edu for inclusion/exclusion criteria
Exclusion Criteria:

• history/current use of cigarette, e-cigarette, vaping or marijuana smoking
• history/current use of nicotine products
• presence of underlying chronic condition
• inability to undergo procedure using IV sedation
• weight < 110 lbs. & BMI > 35 kg/m2
• pregnant and/or breast feeding
• history/current use of chronic immunosuppressive medications
• contact umnsarc@umn.edu for inclusion/exclusion criteria
Breathing, Lung & Sleep Health, Respiratory System
Sarcoid, Lung, Pulmonary, Sarcoidosis, Clinics and Surgery Center (CSC)
I'm interested
Share via email

A double-blind, randomized, placebo-controlled study to assess the safety and efficacy of nebulized PC945 when added to systemic antifungal therapy for the treatment of refractory invasive pulmonary aspergillosis

The purpose of this study is to learn about the safety and efficacy of PC945 when given in combination with the antifungal therapy that is normally given for this condition, also known as the standard of care (SoC). This study will also assess how PC945 is processed in the body (e.g., distributed, transformed, and removed) by measuring the levels of PC945 in your blood and lungs; this is called pharmacokinetics (PK).

Jo-Anne Young, MD
18 years and over
This study is NOT accepting healthy volunteers
STUDY00017568
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• diagnosis of invasive pulmonary aspergillosis that hasn't responded to treatment
Exclusion Criteria:

• surgical or medical condition that makes participation difficult or potentially unsafe
• require care in an intensive care unit
Breathing, Lung & Sleep Health, Infectious Diseases
Clinics and Surgery Center (CSC), antifungal therapy, aspergillosis, fungal infection, lung infection, pulmonary aspergillosis
I'm interested
Share via email
See this study on ClinicalTrials.gov

Quality of life in patients who have undergone different treatments for upper airway stenosis

The objective of the study is to define quality of life in patients with upper airway stenosis after bypassing the stenosis with either tracheotomy or t-tube stenting. Participants complete surveys over 2 years to collect quality of life information.

Raluca Gray
18 years and over
This study is NOT accepting healthy volunteers
STUDY00015986
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• diagnosis of upper airway stenosis treated with tracheotomy or t-tube.
• seen at the Lions Voice Clinic
• at least 18 years old
• able to complete questionnaires in English without help
Exclusion Criteria:

• require mechanical ventilation
• neurological conditions such as stroke, cerebral palsy, neurodegenerative disease.
• new diagnosis (less than 1 year) of head and neck cancer as the indication for tracheotomy
Breathing, Lung & Sleep Health, Ear, Nose & Throat
Montgomery t-tube, airway stenosis, stenosis, t-tube, trach, tracheotomy, Clinics and Surgery Center (CSC)
I'm interested
Share via email

Vibrotactile stimulation of the larynx to treat unexplained chronic cough

This is a study of adults with unexplained chronic cough between 18-80 years old. This study is trying to determine whether a noninvasive vibrotactile stimulation device can help reduce cough symptoms.

Stephanie Misono
18 years and over
This study is NOT accepting healthy volunteers
STUDY00012174
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• adults aged 18-80
• more than 8 weeks of non-productive cough
• chest x-ray or chest CT negative (collected as part of routine clinical care); no time limit on imaging (if available)
• clinical impression that untreated or inadequately treated gastroesophageal, pulmonary, and/or sinus or nasal issue is not the reason for the cough
• able to read and speak English
Exclusion Criteria:

• current smoker or quit less than 3 months ago
• infectious cause for cough (e.g., TB, pertussis, COVID)
• history of known or suspected aspiration pneumonia
• recent intubation/neck surgery (within 8 weeks)
• neuromuscular impairment that may affect cough/laryngeal sensation and/or function (e.g., multiple system atrophy, Parkinson, CVA)
• untreated carotid artery disease
• electronic implants (e.g., pacemaker)
• specific medications (study staff will discuss)
• anticipate use of new medications to treat the cough during the period of the study
• currently having speech therapy for cough
• BMI > 40 (for transmission of VTS through soft tissue)
• allergy to adhesives
• drug/alcohol dependency or abuse
• pregnant
• without regular access to wifi and internet
Breathing, Lung & Sleep Health, Ear, Nose & Throat
chronic cough, cough, larynx, vibrotactile stimulation, Clinics and Surgery Center (CSC)
I'm interested
Share via email
See this study on ClinicalTrials.gov

Post-operative Sore Throat and Gum Chewing for Long Duration LMA Use

The purpose of this study is to determine if chewing gum immediately prior to transport to the operating room reduces the severity of post-operative sore throat in patients who have an LMA placed for procedures with duration greater than 1 hour.

Jacob Hutchins
18 years and over
This study is NOT accepting healthy volunteers
STUDY00012614
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• having outpatient ambulatory surgery
• receiving general anesthesia utilizing a laryngeal mask airway
• surgery expected to last longer than 1 hour
Exclusion Criteria:

• chronic laryngitis
• chronic bronchitis
• asthma
• gastroesophageal reflux disease
• smoked within the last week
• non-English speaking
Breathing, Lung & Sleep Health
Clinics and Surgery Center (CSC), Anesthesia, Surgery
I'm interested
Share via email
See this study on ClinicalTrials.gov